Defects in the O-linked glycosylation of the peripheral membrane protein α-dystroglycan (α-DG) are the main cause of several forms of congenital muscular dystrophies and thus the characterization of the glycosylation of α-DG is of great medical importance. A detailed investigation of the glycosylation pattern of the native α-DG protein is essential for the understanding of the biological processes related to human disease in which the protein is involved. To date, several studies have reported novel O-glycans and attachment sites on the mucin-like domain of mammalian α-DG with both similar and contradicting glycosylation patterns, indicating the species-specific O-glycosylation of mammalian α-DG. By applying a standardized purification scheme and subsequent glycoproteomic analysis of native α-DG from rabbit and human skeletal muscle biopsies and from cultured mouse C2C12 myotubes, we show that the O-glycosylation patterns of the mucin-like domain of native α-DG are conserved among mammalians in a region-specific manner.
Introduction
The disorders of congenital muscular dystrophies (CMDs) are a heterogeneous group of autosomal recessive disorders that show a broad range of severity of symptoms. Defects in the O-linked glycosylation of the peripheral membrane protein α-dystroglycan (α-DG) are the main cause of several forms of CMDs denoted dystroglycanopathies. α-DG contains rare O-mannose-linked structures important for interactions between α-dystroglycan and the extracellular matrix proteins and aberrant glycosylation of α-DG is strongly associated with CMDs. Chiba et al. (1997) identified the first O-mannosylated structure, Neu5Acα3Galβ4GlcNAcβ2Man-O-Ser/Thr (sialyl-N-acetyllactosamine-mannose, sLacNAc-Man) on α-DG from bovine peripheral nerve (Endo and Manya 2006) . The perturbation of the biosynthesis of the O-mannosyl structures of α-DG leads to hypoglycosylation and abolishes ligand-binding activity. Mutations in enzymes involved in the biosynthesis of the sLacNAc-Man are the main reasons for the structural and functional brain and muscle abnormalities observed in many of the dystroglycanopathies (Brockington et al. 2001; Mercuri et al. 2003; Poppe et al. 2003; Beltran-Valero de Bernabe et al. 2004; Mercuri, D'Amico, et al. 2006; Mercuri Topaloglu et al. 2006; Godfrey et al. 2007; Jimenez-Mallebrera et al. 2009 ) and are therefore of great medical interest. In the past few years, several O-linked glycans and their corresponding attachment sites have been reported in the literature adding new information to the complex pattern of O-glycosylation on mammalian α-DG (Nilsson et al. 2010; Stalnaker et al. 2010; Yoshida-Moriguchi et al. 2010; Harrison et al. 2012) . Among them, a novel trisaccharide GalNAcβ3GlcNAcβ4Man bearing a 6-O-phosphorylation at the mannose residue (YoshidaMoriguchi et al.) and a glucosaminoglycans (GAG)-like structure of repeating (-3-xylose-α1,3-glucuronic acid-α1-) units (Inamori et al. 2012 ) have been directly implicated in the binding capacity of α-DG. The dystroglycan gene is highly conserved among species and the predicted molecular mass of the core protein is 72 kDa. However, due to differences in glycosylation, the observed molecular weight of α-DG ranges between 120 and 156 kDa among different tissues (Ibraghimov-Beskrovnaya et al. 1992; Ibraghimov-Beskrovnaya et al. 1993; Yamada et al. 1994; Leschziner et al. 2000; Barresi and Campbell 2006) . Previous studies aimed to characterize the O-glycosylation core structures and the site occupancy of native rabbit and human skeletal muscle α-DG showed similar results regarding the O-GalNAc and O-Man core structures but differences in the site occupancy of the O-mannosylated glycans (Nilsson et al. 2010; Stalnaker et al. 2010) . In order to investigate if the discrepancy between the studies were due to differences between species or purification protocols, we have enriched and purified native α-DG from rabbit and human skeletal muscle biopsies as well as from cultured mouse C2C12 myotubes using a standardized protocol of wheat germ agglutinin (WGA)-chromatography and subsequent immunoprecipitation using the VIA-4 antibody.The data revealed a highly regionspecific glycosylation where the O-Man-initiated glycans were concentrated to the N-terminal part of the mucin-like domain and the O-GalNAc-initiated glycans were exclusively found at the C-terminal part of the domain. Consequently, the O-glycosylation of native α-DG is conserved among mammalians in a region-specific manner.
Results
The HexHexNAcHex-O core structures on α-DG from mouse C2C12 myotubes showed a large degree of heterogeneity of the terminal modifications For each analysis, Mascot database searches identified the dystroglycan precursor protein [Uniprot ID: Q14118 (human), Q28685 (rabbit) and Q62165 (mouse)] as the top scoring protein. For both human and rabbit, 6 non-glycosylated peptides from the C-terminal domain of α-DG were identified, whereas for the mouse sample, 14 and 2 non-glycosylated peptides from the C-and N-terminal domains were identified, respectively (P < 0.05 for each peptide, Supplementary data, Table S1 ). A multitude of glycosylated peptides were found in the MS/MS (MS 2 ) and MS/MS/MS (MS 3 ) collision-induced dissociation (CID) fragmentation spectra. Glycopeptides were identified based on the presence of diagnostic sugar oxonium-ion fragments and by glycosidic linkage fragmentation patterns as described previously (Huddleston et al. 1993; Nilsson et al. 2010) . The monoisotopic mass of precursor ions obtained by high-accuracy mass measurements was analyzed with the GlycoMod tool (Figure 1 , Supplementary data, Table S1 ) to generate a list of candidate tryptic glycopeptides deduced from the α-DG sequence within a 10-ppm mass error window. The observed fragmentation patterns in the CID-MS 2 and CID-MS 3 spectra were manually inspected to confirm the suggested glycopeptide identity and to assess the glycan structure, in particular regarding whether the core was based on O-linked N-acetylhexosamine (HexNAc-O-Ser/Thr) or O-linked hexose (Hex-O-Ser/Thr) (Figure 1 and Supplementary data, Figures A1-A29, B1-B16 and C1-C68). As before, we identified glycopeptides originating from the p360-371 (DPVPGKPTVTIR) region containing HexHexNAcHex-Oand/or Neu5AcHexHexNAcHex-O-glycans on the two available Thr residues in support of the reported Neu5Acα3Galβ4GlcNAcβ2Manα1Ser/Thr structure for α-DG ( Figure 1B) . Also, for the mouse sample, we identified corresponding glycopeptides terminated with N-glycolylneuraminic acid (Neu5Gc) instead of N-acetylneuraminic acid (Neu5Ac) ( Figure 1C ), thus showing an extra mass of 16 Da on the Neu5Gc-containing fragments, e.g. m/z 673 vs 657 for the Neu5GcHexHexNAc and Neu5AcHexHexNAc oxonium ions, respectively. Further, we identified p360-371 glycopeptides containing an additional Hex ( Figure 1D ) or a deoxyhexose (Fuc; Figure 1E ), instead of the terminal sialic acid, on one or both of the glycans. The Fuc and the additional Hex are most likely positioned on the terminal HexHexNAc of the core structure, as opposed to the Hex-O-Thr, since the m/z 512 (FucHexHexNAc + ) and m/z 528 (Hex 2 HexNAc + ) oxonium ions were prominent in the spectra of the corresponding glycopeptides with Fuc ( Figure 1E ) and an additional Hex ( Figure 1D and F) , respectively. Conversely, m/z 528 was virtually absent in the spectra of the HexHexNAcHex-Oand Neu5AcHexHexNAcHex-O-containing glycopeptides ( Figure 1C) , showing that Hex-O-Ser/Thr was not easily fragmented during the CID conditions used. Also, glycopeptides containing both Fuc and additional Hex on the same glycan were identified, in support of yet another saccharide epitope ( Figure 1F ). See a complete list of all identified mouse DPVPGKPTVTIR glycopeptides in the Supplementary data, Figures C1-C24 .
The human, rabbit and mouse skeletal muscle α-DG have similar O-GalNAc-and O-Man-initiated core structures and site occupancies The mass spectrometric analysis conducted in this study showed that the tryptic glycopeptides of human p360-371 (DPVPGKPTVTIR), rabbit p360-373 (DPVPGKPTVTTRTR) and mouse p358-369 (DPVPGKPTVTIR) were invariably modified with O-mannosyl glycans ( Figure 2A and Supplementary data, Figures A1-A4, B1-B4 and C1-C24). In all cases, the identified glycosidic chains were biosynthetically related to the sLacNAc-Man structure with or without the addition of sialic acid. In the mouse samples, further decoration with Fuc, Hex, Neu5Ac or Neu5Gc could also be detected accounting for the identification of 23 different glycoforms (Figure 2A , Supplementary data, Figures C2-C24 ). The absence of core structure heterogeneity in this region stands in sharp contrast to the observed variation in terminal modifications on the HexHexNAcHex-O-core structure. This strongly indicates that the O-linked mannosylation is strictly regulated at these positions. Moreover, the identical glycosylation patterns clearly indicate that mannosylation on this peptide stretch is conserved among different species.
Glycopeptides originating from the most distal part of the mucin-like domain: human amino acids 462-489, rabbit amino acids 462-489 and mouse amino acids 460-487 were also identified, and this region was completely covered for all three species. This region was predominantly modified by typical mucin O-GalNAc-initiated glycosylations and displayed heterogeneity regarding the glycan core structures and site occupancies ( Figure 2B , Supplementary data, Figures A5-A29, B6-B16 and C25-C68). In addition, some glycopeptides were only detected in the samples from one or two of the species, e.g. the mannosylated p390-402 (VSDAGTVVSGQIR) was only identified in rabbit skeletal muscle. The p448-454 (RPTKKPR) was only identified in human skeletal muscle and p429-447 (VSTPKPATPSTDSTTTTTR) was not identified in the mouse sample. Additionally, traces of O-linked mannosylation were also observed for the mouse glycopeptides p460-468 (VTTKAPITR) and p469-477 (LETASPPTR), shown in Figure 2A . A summary of all identified glycopeptides in this study can be seen in Figure 2A oscillation energy distribution that is specific for this technique ( Figure 3 ). Thus, this approach alone is often not sufficient to completely reveal the structural features of glycopeptides and should be combined with other techniques. Additionally, the lability of post-translational modifications (PTMs) during CID fragmentation makes the site of attachment difficult to determine for peptides containing several serine and threonine residues. In the particular case of the mouse p478-487 (IRTTTSGVPR) bearing six HexNAc residues, the limitations associated with CID for PTM analysis precluded deeper insight into the structure of the modifying glycans and the exact identity of the glycosylation sites ( Figure 3B ). In order to address this issue, we used electron-transfer dissociation (ETD) for the fragmentation analysis of α-DG glycopeptides. During ETD, protonated species are fragmented by a gasphase ion-ion reaction using radical anions as an electron transfer vehicle. In the particular case of peptides and glycopeptides, ETD fragmentation induces the cleavage of the N-C α bonds of the peptide backbone generating homologous O-Glycosylation of mammalian α-dystroglycan series of c-and z-fragment ions. More importantly, this is a low-energy reaction pathway that preserves the glycans and hence provides site-specific information.
The ETD analysis of precursor ions at m/z 769.4, previously characterized by CID-MS 2 and CID-MS 3 ( Figure 3D and E) as the mouse p478-487 (IRTTTSGVPR) bearing six HexNAc residues, confirmed the peptide sequence identity and showed specific glycan modifications at Thr 480 , Thr 481 and Thr 482 ( Figure 3F ). The presence of the series of fragment ions c 3 , c 4 and c 5 proved that each modified glycosylation site carried a HexNAc-HexNAc-O-glycosidic chain ruling out potential branched or more extended linear structures. An unexpected finding was the observation of a high intensity ion at m/z 1537.31 which was tentatively assigned as a triply charged dimer. This phenomenon was consistent in all ETD spectra of triply charged glycopeptides (Supplementary data, Figures F1-F12) .
Interestingly, the mouse p460-468 (VTTKAPITR) was identified with HexNAc-HexNAc-O glycans at Thr Figure F10 ) but also with Neu5AcHexHexNAc-O modification (Supplementary data, Figure F11 ) showing core structure heterogeneity. Additionally, the ETD analysis of precursor ions at m/z 778.7, previously characterized as mouse p358-369 (DPVPGKPTVTIR) bearing two HexHexNAcHex-O glycans ( Figure 3B ), confirmed these specific glycan structures at Thr 365 and Thr 367 ( Figure 3C ) on this peptide. Several other glycopeptides, derived from the mouse α-DG, were also analyzed by ETD, confirming the peptide sequence and providing site-specific information on the modifying glycans (Supplementary data, Figures F1-F12 ).
Label-free relative quantifications of glycopeptides revealed the dominating glycoforms of VIA-4 immunopurified O-GalNAc-and O-Man-initiated core structures from mouse skeletal muscle α-DG One of the most striking findings in this study was the observation of the large heterogeneity and complexity regarding both core structures and terminal decorations of glycan chains. The largest variation was found in the samples derived from C2C12 mouse myotubes probably due to a higher α-DG concentration in the purified material compared with the minute amounts that are expected to be enriched from human and rabbit small-sized muscle biopsies. For the mouse samples, besides O-mannosylation, we observed the presence of extended structures and unassigned HexNAc-HexNAc-O-Ser/ Thr core structures. Terminal glycan decorations with Fuc, Hex, Neu5Ac and Neu5Gc could also be unequivocally confirmed. Thus, to our knowledge, this is the first time that structural evidence is presented for mammalian O-linked mannosyl glycans decorated with Neu5Gc, Neu5Ac or terminal hexoses, alone or with Fuc.
Given the high quality of the experimental data and the vast structural variation that emerged from the initial mass spectrometric analysis, we kept focusing on the mouse samples to perform a relative quantification of the different glycoforms. The relative quantification of glycopeptides was conducted using a label-free approach. Extracted base peak ion chromatograms for all identified glycopeptides in the C2C12 mouse myotubes samples were generated using the Xcalibur 2.1 software (Supplementary data, Figures D and E1-E59). 
O-Glycosylation of mammalian α-dystroglycan
Thus, we were able to quantify the relative abundance of 23 different glycoforms of the p358-369, (DPVPGKPTVTIR) glycopeptide that exhibited the largest diversity in terms of terminal decorations and site occupancies. More importantly, this entire set of related glycopeptides was invariably O-mannose-initiated reflecting different biosynthetic intermediates and end-products of the LacNAc-Man structure. As stated before, modification with Fuc was readily observed but rearrangement involving these very residues precluded the confident assignment of the position of Fuc in the glycan chain (Wuhrer et al. 2011) . Consequently, fucosylated glycopeptides were treated for quantification as unique glycoforms, although heterogeneity at this level could not be completely ruled out. Notably, fucosylation was exclusively restricted to the O-mannosyl structures and was not identified on GalNAc-O-initiated core structures.
The relative quantification revealed that glycopeptides modified with two HexHexNAcHex-O-Thr chains on the p358-369 were highly predominant (40%), whereas glycopeptides decorated with only one HexHexNAcHex-O-Thr glycans were less than 1% ( Figure 4A ). This finding clearly indicates that both possible glycosylation sites were generally modified.
Terminations with one Neu5Ac residue were most abundant (15%) followed by the attachment of one Hex (12%). Modifications with Neu5Gc and Hex together with Fuc were 1% or less, whereas HexHexNAcHex-O only decorated with one or two Fuc were more commonly present (5% and 6%, respectively). In addition, we found that, in this series, the HexHexNAcHex-O-Thr chain was present on at least one of the two potential glycosylation sites. Earlier intermediates such as Hex-O-Ser/Thr or only HexNAcHex-O-Ser/Thr were not detected at all.
The p469-477 (LETASPPTR) and the p460-468 (VTTKAPITR) were also subjected to relative quantification ( Figure 4B ). Both glycopeptides displayed high heterogeneity regarding core structures and the abundance of core 1-like, core 2-like and unassigned HexNAc-HexNAc-O-core structure, as well as O-mannosylation was determined. It was evident that for the p469-477 (LETASPPTR) only one or two positions could be modified by glycosylation, even though three potential glycosylation sites are available. Glycoforms simultaneously bearing one sialylated core 1-like glycan and one non-sialylated HexNAc-HexNAc-O-glycan sequence accounted for almost 60% of the total population. The second most abundant glycoform was modified by two monosialylated core 1-like glycans (15%) and third most abundant by one mono-sialylated core 1-like glycan and one di-sialylated core 1-like glycan (13%). Trace amounts of O-linked mannosylation were observed at only one position in the form of one Hex-O-Ser/Thr (2%) or one Neu5AcHexHexNAcHex-O structure (less that 1%), clearly indicating that mannosylation at this sites occurs at substoichiometric levels in native α-DG. For the p460-468 (VTTKAPITR), all three potential glycosylation sites exclusively modified by HexNAc-HexNAc-O-glycosidic chains accounted for 49% of the signal, whereas glycoforms bearing three sialylated core 1-like glycans were less abundant (12%). Also at this position, the presence of mannosylation in the form of one Neu5AcHexHexNAcHex-O structure was substoichiometric (3%) ( Figure 4B ).
The O-Man and O-GalNAc core structures on the mucin-like domain of α-DG reveal a conserved region-specific glycosylation pattern The glycopeptides from human and rabbit skeletal muscle and mouse myotubes displayed the same O-Hex-and O-HexNAcinitiated structures on glycopeptides belonging to homologous protein sequence stretches. By mapping of the O-Man-and O-GalNAc-initiated structures identified in this study and including all previously reported O-Man and O-GalNAc sites, the deduced data revealed separate O-Man and O-GalNAcinitiated domains within the mucin-like domain ( Figure 5 ). The O-Man-initiated structures were predominantly present in the 313-425 region and the O-GalNAc-initiated structures were localized in the 429-490 region ( Figure 5 ). Thus, except for the rabbit skeletal muscle, the first, N-terminal part of the mucin-like domain is decorated with O-Man-initiated structures and the second part with O-GalNAc-initiated structures. Thus, although the glycosylation of native α-DG shows core structure and site occupancy heterogeneity, the positions of the O-Man and O-GalNAc-initiated structures is conserved among mammalian in a region-specific manner.
Discussion
By purifying native α-DG from human and rabbit skeletal muscle biopsies and from cultured mouse C2C12 myotubes, using a standardized protocol of WGA chromatography and subsequent immunoprecipitation, we identified 35, 16 and 84 tryptic peptides and glycopeptides from human, rabbit and mouse myotubes, respectively. We identified the same six tryptic glycopeptides p360-371, p429-447, p455-461, p462-470, p471-479 and p482-489 from the mucin-like domain of rabbit and human α-DG and additionally the p390-402, which was only identified from rabbit skeletal muscle. In the mouse α-DG sample, we identified the corresponding tryptic glycopeptides p358-369, p453-459, p460-468, p469-477 and p478-487. Five of the glycopeptides ( p429-447, p455-461, p462-470, p471-479 and p482-489) showed HexNAc-O-Ser/Thr-initiated structures (O-GalNAc) and displayed heterogeneity regarding both the glycan core structures and the site occupancies. The common p360-371 and rabbit p390-402 glycopeptides showed only Hex-O-Ser/Thr-initiated structures indicative for O-linked mannose. In this study, we were not able to identify any phosphorylated glycans or the like-acetylglucosaminyltransferase (LARGE)-induced GAG-like structure on α-DG from any of the species. This is mainly due to the glycoproteomic technique used, which was performed using positive-ion tandem mass spectrometry which not favoring the ionization of acidic glycans such as phosphorylated glycans or GAG structures. Therefore, the negative-ion mode should be considered for the analysis of these modifications on α-DG.
Recently, several reports have added new information helping us to build a map of the complex pattern of O-glycosylation on mammalian α-DG ( Figure 5) . Two independent studies, aimed to characterize the O-glycosylation core structures and site occupancy of native rabbit and human skeletal muscle α-DG, showed similar results regarding the O-GalNAc and O-Man core structures but differences in the site occupancy of the A Gomez Toledo et al.
O-Man structures (Nilsson et al. 2010; Stalnaker et al. 2010) . O-Man was found on several positions in the mucin-like domain from rabbit skeletal muscle but not within the glycopeptide sequence p360-373, which was in contrast to the findings from native human skeletal muscle α-DG (Nilsson et al. 2010) . Furthermore, the glycopeptides p471-479 and p O-Glycosylation of mammalian α-dystroglycan 480-489 were identified with only O-GalNAc-initiated glycans from human skeletal muscle but identified with both O-GalNAc and/or O-Man-initiated structures on α-DG from rabbit (Nilsson et al. 2010; Stalnaker et al. 2010) .
The findings reported here give further support that the glycopeptide sequence p360-373 is O-mannosylated in all species and the discrepancy obtained for rabbit skeletal muscle α-DG may be due to differences in the purifications or mass spectrometric analysis of α-DG. In both studies, lectin chromatography using WGA was used before lamininsepharose affinity purification of the rabbit skeletal muscle α-DG, whereas in both this and the previous study, human skeletal muscle α-DG was immunoprecipitated using the VIA-4 antibody. The VIA-4 antibody recognizes glycan epitopes on α-DG but the binding is not inhibited by laminin, suggesting that the antibody recognizes another glycan epitope than the binding site of laminin (Ervasti and Campbell 1993) . Consequently, different glycoforms of native human and rabbit skeletal muscle α-DG may have been purified and characterized which may explain the discrepancy. However, Harrison et al. recently characterized the glycosylation pattern of recombinant mouse α-DG expressed in human embryonic kidney 293 (HEK293) cells. The secreted α-DGFc fusion protein was directly affinity purified using protein G without prior lectin chromatography, and thus, the purification was the independent of glycosylation and binding specificity of the recombinant α-DG and yet showed the same glycosylation pattern on the p361-371 glycopeptide as in this study.
Mutations in the glycosyltransferase POMT1, POMT2 and POMGnT1 genes, which are known to be involved in the biosynthesis of LacNAc-Man, lead to hypoglycosylation and are the known cause for several dystroglycanopathies (Michele et al. 2002) . Consequently, defects in the biosynthesis of the LacNAc-Man structure are associated with dystroglycanopathies and thus are a diagnostic structure, suggesting that it may be involved in the ligand-binding capacity of α-DG to the extracellular matrix. However, the digestions of α-DG with a combination of enzymes that degraded the sLacNAc-Man structure rather enhanced than diminished binding to laminin-1 (Combs and Ervasti 2005) . Notably, the minimal common O-Man-initiated structure identified in this study was LacNAc-Man. In the mouse C2C12 sample, 35% of all identified glycopeptides in this study belonged to the sequence p358-369 DPVPGKPTVTIR, which was exclusively occupied with LacNAc-Man core structure. Although the LacNAc-Man structure showed large heterogeneity with the modification of Fuc, Hex, Neu5Ac and Neu5Gc, the relative quantification of identified glycopeptides supported that the LacNAc-Man structure is the dominating glycoform, indicating that the LacNAc-Man structure may be the binding epitope of the VIA-4 antibody. Furthermore, in this study, the mouse p460-468 and p469-477 glycopeptides were identified with both LacNAc-Man-and O-GalNAc-initiated structures not identified on the secreted α-DGFc fusion protein reported by Harrison et al. which further support that the binding specificity of the VIA-4 antibody may be toward the LacNAc-Man structure. However, this needs to be shown experimentally.
By mapping of the O-Man-and O-GalNAc-initiated structures, we show that the O-Man-and O-GalNAc-initiated structures were specifically localized into different parts of the mucin-like domain. More specifically, the O-Man-initiated structures were predominantly present in the 313-425 region and the O-GalNAc-initiated structures were localized in the 429-490 region ( Figure 5 ). Except for the rabbit skeletal muscle, as already discussed, the first part of the mucin-like domain consists of O-Man-initiated structures and, the second, C-terminal part consists of O-GalNAc-initiated structures. It has been suggested that the O-mannosylation regulates the O-glycosylation of the mucin-like domain of α-DG in a sequential manner (Furukawa et al. 2008) . By assaying the protein O-mannosyltransferase (POMT) activity using microsomal membrane fractions of POMT1-and POMT2-transfected HEK293 cells toward a series of synthetic peptides covering the mucin-like domain of α-DG, six O-mannosylated threonines within the mucin-like domain were identified. The authors suggested that the O-mannosylation on α-DG is regulated by the consensus sequence IXPT(P/X)TXPXXXXPTX(T/X) XX (Manya et al. 2007 ). Breloy et al. used 10 constructs of differently truncated human α-DG probes and 3 human MUC1-α-DG fusion probes covering the mucin-like domain of human α-DG. The probes were expressed in HEK293 cells and two regions, amino acids 390-433 and 455-489, were determined to be O-mannosylated, and the authors suggested that the O-mannosylation is controlled by regions both within and upstream of the mucin-like domain of α-DG (Breloy et al. 2008) . The region within the mucin-like domain was proposed to cover the amino acids 377-405, which included the consensus sequence suggested by Manya et al. By using a synthetic peptide covering this suggested region, we were not able to add mannose to the synthetic peptide (data not shown), which may support that further upstream sequences are needed. In fact, recently, a patient with a single missense mutation, T192M, within the N-terminal part of α-DG was identified. The immunohistochemistry analysis of muscle biopsies from this patient showed the hypoglycosylation of α-DG (Dincer et al. 2003; Hara, Balci-Hayta, et al. 2011) , supporting the hypothesis that regions upstream from the mucin-like domain are important for the correct glycosylation of α-DG. In addition, it has been shown that the N-terminal part of α-DG is necessary for LARGE-induced glycosylation (Kanagawa et al. 2004) . Recently, the TPTPV sequence, which includes the Thr 317 and Thr 319 , was shown to be the direct target for the LARGE-dependent modification of O-mannosylated glycans on the mucin-like domain of α-DG . Shortly after, it was also shown that LARGE is responsible for the biosynthesis of a novel GAG-like structure, acting as a bifunctional glycosyltransferase, displaying both xylosyltransferase and glucuronyltransferase activities (Inamori et al. 2012) . This short sequence is highly conserved and is uniquely present at this position and one may speculate that the TPTPV sequence may be the "starting point" for O-mannosylation. A recent report suggests that O-mannosylation controls the addition of GalNAc residues at specific position on two synthetic peptides (Tran et al. 2012) . By in vitro enzymatic assay using ppGalNAc-Ts on two peptides corresponding to the amino acids 419-427 (PPTTTTKKP) and 479-489 (RIRTTTSGVPR) that were either mannosylated in different positions or un-glycosylated prior to the enzymatic assay, the author suggested that the presence and specific location of O-Man determines sites for the addition of O-GalNAc. The p480-489 that corresponds to the synthetic peptide amino acids 479-489 used in the study was identified with a minor presence of O-Man in native rabbit skeletal muscle and reported by Stalnaker et al. (2010) . However, this is in contrast to the findings in this study where the p480-489 (or p478-487 in mouse) was only identified with O-GalNAcinitiated structures ( Figure 5 ). As the O-GalNAc-initiated structures are concentrated to the most C-terminal part of the mucin-like domain, it is likely that the O-mannosylation controls further glycosylation in a region-specific manner. Thus, although the O-mannosylation may regulate further glycosylation, the glycosylation of α-DG may also be regulated by yet unidentified sequences and systematic studies are needed in order to identify these motifs and how they coordinate the O-Man and O-GalNAc glycosylation of the mucin-like domain of native mammalian α-DG together with an upstream sequence likely to be involved.
In this study, we characterized the native α-DG from rabbit and human skeletal muscle biopsies by using the same standardized purification protocol. Since most studies have been performed using recombinant α-DG overexpressed in cultured cells, we also purified the native α-DG from cultured mouse C2C12 myotubes. The muscle fiber maturation is incomplete in the cultured C2C12 cells compared with the human and rabbit skeletal muscle and indeed, we found a high degree of structural heterogeneity, which may be due to culture conditions. Nevertheless, the site occupancy of the O-Man-and O-Glycosylation of mammalian α-dystroglycan O-GalNAc-initiated structures on native α-DG was consistent with the pattern observed for the native α-DG from mature human and rabbit skeletal muscle fibers, supporting our conclusion that the O-glycosylation of native α-DG is conserved among mammalians in a region-specific manner.
Materials and methods
Sample preparation Approximately 0.1 g of one sample of fresh frozen human and rabbit skeletal muscle was homogenized in Denaturing Cell Extraction Buffer (Invitrogen BV, Life Technologies Europe B.V, Belgium) and Protease inhibitor cocktail (Sigma Aldrich, St Louis, MO) as described previously (Nilsson et al. 2010) .
The mouse C2C12 cells (ATCC) were cultured in Dulbeco's modified Eagle's medium (DMEM) (Gibco, Life Technologies Europe B.V, Belgium) supplemented with 10% fetal bovine serum (Gibco), 2 mM L-glutamine (Gibco) and 50 µg/mL of gentamicin (Laboratorios Normon, Madrid, Spain) and incubate at 37°C in a humidified atmosphere incubator with 5% CO 2 . The cells were differentiated by replacing the growth medium with differentiation medium consisting of DMEM containing 2% horse serum (Gibco), 2 mM L-glutamine and 50 µg/mL of gentamicin. After 4 days, the differentiated myotubes were lysed in a cell lysis buffer containing 50 mM Tris-HCl, 100 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 2 µg/mL aprotinin, 0.5 µg/mL leupeptin, 1 µg/mL pepstatin A, 0.1 mM phenylmethylsulfonyl fluoride and 1× Complete Mini ethylenediaminetetraacetic acid-free protease inhibitor cocktail (Roche Diagnostics, Scandinavia AB, Sweden). The protein concentrations of the crude cell extracts were determined using the Bradford protein assay. The crude skeletal muscle extracts and 0.1 g of C2C12 cell extract were, as described previously (Nilsson et al. 2010) , subjected to glycoprotein enrichment by WGA-affinity chromatography followed by immunoprecipitation using the VIA-4 antibody, recognizing glycan epitopes on α-DG. The immunoprecipitated protein samples were separated by SDS-polyacrylamide gel electrophoresis chromatography, proteins were visualized by colloidal Coomassie staining and gel bands corresponding in size to α-DG were in-gel digested. To obtain a visible band after Coomassie blue staining, in total, 2 mg of WGA-enriched C2C12 glycoprotein was immunopurified.
Nano-liquid chromatography tandem mass spectrometry analysis The nano-LC-MS/MS analyses were performed as described in Nilsson et al. (2010) and were performed at the proteomic core facility at the Sahlgrenska Academy, University of Gothenburg, and by the proteomics group at the Laboratory for Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg.
Data analysis
Identification of proteins and peptides was performed by automated database search; using the in-house version of the Mascot software (Mascot version 2.2, http://www. matrix-science.com), LTQ.raw files were converted to .dta files by the XCalibur software utility extract_msn (Thermo Fisher Scientific, Ontario, Canada). The search was performed against Homo sapiens (human; 20 254 sequences), Mus musculus (mouse; 16 360 sequences) and mammals (65 528 sequences) in the UniprotKB/Swiss-Prot database (533 657 sequences; 189 261 966 residues). The other search parameters were set as follows: MS accuracy, 10 ppm, MS/MS accuracy, 0.6 Da, enzyme, trypsin or semitrypsin, one missed cleavage site was allowed, fixed carbamidomethyl modification of cysteine and variable oxidation of methionine. All glycopeptides were manually assessed to validate the glycan composition and structure.
The Glycomod application (http://web.expasy.org/glycomod/) was used to identify the glycopeptides based on the identified glycan composition from the MS 2 and MS 3 analysis.
The label-free relative quantification of glycopeptides Extracted base peak ion chromatograms for all identified glycopeptides were generated using the Xcalibur 2.1 software (Thermo Fisher Scientific). For every chromatographic peak, the area under curve was computed as a measurement of the ion abundance. Every glycopeptide was expressed as a percentage of the total ion abundance of all glycopeptides containing exactly the same amino acid sequence and detected in the same MS-running.
Supplementary data
Supplementary data for this article is available online at http://glycob.oxfordjournals.org/. 
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